6634.TWO Sinew Pharma Inc.
- Market cap
- TWD 3.96B
- P/E
- -
- P/B
- 3.78x
- ROE
- -11.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6634.TWO undervalued?
Graham numberThe Graham number of Sinew Pharma Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sinew Pharma Inc. fundamental analysis
No fundamental analysis for Sinew Pharma Inc. yet.
Sinew Pharma Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sinew Pharma Inc.
Sinew Pharma Inc., a biopharmaceutical company, focuses on the research, development, and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase IIa clinical trial and SNP-630 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan. It is also developing SNP-810 is in phase II clinical trial for use in pain relief and fev…
Full company profileSinew Pharma Inc. financial statements
Sinew Pharma Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 462K | 6.23M | 328K | 0.00 | 0.00 | 47.0K |
| Gross Profit | - | 324K | 5.09M | 290K | -29.0M | -30.3M | 37.0K |
| Operating Income | -76.0M | -84.1M | -94.4M | -148M | -186M | -169M | -140M |
| EBITDA | -57.8M | -59.9M | -68.8M | -117M | -164M | -120M | -104M |
| Net Income | -76.2M | -82.0M | -91.6M | -140M | -171M | -150M | -124M |
| EPS | -1.94 | -1.60 | -1.54 | -2.02 | -2.43 | -2.11 | -1.74 |
| Balance Sheet | |||||||
| Total Assets | 421M | 453M | 1.58B | 1.49B | 1.36B | 1.23B | 1.13B |
| Total Liabilities | 252M | 17.4M | 16.0M | 28.7M | 39.7M | 28.9M | 36.4M |
| Shareholders' Equity | 169M | 436M | 1.57B | 1.46B | 1.32B | 1.20B | 1.09B |
| Cash & Short-term Investments | 293M | 338M | 1.48B | 1.39B | 1.28B | 1.16B | 25.3M |
| Total Debt | 5.18M | 3.34M | 1.05M | 7.55M | 9.28M | 2.82M | - |
| Cash Flow | |||||||
| Operating Cash Flow | -58.7M | -59.3M | -57.3M | -93.8M | -118M | -106M | -95.3M |
| Capital Expenditure | 6.66M | 2.69M | 5.87M | 5.88M | 7.45M | 1.33M | 1.87M |
| Free Cash Flow | -65.4M | -62.0M | -63.2M | -99.6M | -125M | -107M | -97.2M |
| Ratios | |||||||
| ROE | -45.2% | -18.8% | -5.8% | -9.6% | -12.9% | -12.6% | -11.3% |
| ROA | -18.1% | -18.1% | -5.8% | -9.4% | -12.5% | -12.3% | -11.0% |
| Net Profit Margin | - | -17,751.3% | -1,470.1% | -42,737.8% | - | - | -263,287.2% |
| Debt to Equity | 0.03x | 0.01x | 0.00x | 0.01x | 0.01x | 0.00x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sinew Pharma Inc. dividends
Sinew Pharma Inc. has not paid dividends in the last 7 fiscal years.
Who owns Sinew Pharma Inc.
Ownership data of Sinew Pharma Inc. is not available yet.
Sinew Pharma Inc. company profile
- Company name
- Sinew Pharma Inc.
- Ticker
- 6634.TWO
- ISIN
- TW0006634009
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 52
- Fiscal year end
- December
- Address
- C516, Building C, Taipei, Taiwan, 11571
- Phone
- 886 2 2788 5365
- Website
- sinewpharma.com
About Sinew Pharma Inc.
Sinew Pharma Inc., a biopharmaceutical company, focuses on the research, development, and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase IIa clinical trial and SNP-630 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan. It is also developing SNP-810 is in phase II clinical trial for use in pain relief and fever reduction; SNP-820 is in Phase II clinical trial for antidote for acetaminophen poisoning, and SNP-830 and SNP-840, which in pre-clinical trial are used as hepatotoxicity-free analgesic medicines in the United States. Sinew Pharma Inc. was founded in 2014 and is based in Taipei City, Taiwan.
Sinew Pharma Inc. management
4- Dr. Kai-Min Chu M.D., Ph.D.Chairman & CEO
- Mr. Cheng-Hui Hsiung Ph.D.COO & Director
- Ms. Tzu-Wen ChenChief Financial Officer & Accounting Supervisor
- Ms. Hsin-Tien HoChief Technology Officer